Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
14 janv. 2025 01h00 HE
|
Sandoz Group
MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilarsLeading in home market...
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
17 déc. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz takes further steps to resolve legacy US generic drug antitrust class action litigation Sandoz US has entered into a...
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
15 nov. 2024 01h00 HE
|
Sandoz Group
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for...
Sandoz reports third-quarter and nine-month 2024 sales
30 oct. 2024 02h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and...
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
11 oct. 2024 01h00 HE
|
Sandoz Group
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for metastatic breast cancerLaunch expected to be...
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
12 août 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degenerationFurther enhances leading US...
Sandoz reports second-quarter sales and half-year 2024 results
08 août 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches...
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
25 juil. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across...
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
01 juil. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe)...
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
22 mai 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all...